Compass Therapeutics annual shareholders’ equity
2019
2019
2020
2020
2021
2022
2023
2024
2025
Compass Therapeutics Shareholders’ Equity Growth & History (CMPX)
Compass Therapeutics's shareholders’ equity was $196.8M for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $196.8M | $71.6M | +57.14% |
| 2024 | 2024-12-31 | $125.2M | −$23.3M | −15.69% |
| 2023 | 2023-12-31 | $148.5M | −$33.1M | −18.22% |
| 2022 | 2022-12-31 | $181.6M | $41.6M | +29.67% |
| 2021 | 2021-12-31 | $140.1M | $100.1M | +250.68% |
| 2020 · Dec 31 | 2020-12-31 | $39.9M | $28.7M | +254.53% |
| 2020 · Mar 31 | 2020-03-31 | −$124.8M | −$124.7M | — |
| 2019 · Dec 31 | 2019-12-31 | $11.3M | — | — |
| 2019 · Mar 31 | 2019-03-31 | −$70,589 | — | — |
Compass Therapeutics quarterly shareholders’ equity
As of Mar 31, 2018
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q4.19
Q4.20
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $166.0M | $72.8M | +78.15% |
| Q1 2026 | 2026-03-31 | $186.5M | $76.2M | +69.09% |
| Q4 2025 | 2025-12-31 | $196.8M | $71.6M | +57.14% |
| Q3 2025 | 2025-09-30 | $209.6M | $71.2M | +51.46% |
| Q2 2025 | 2025-06-30 | $93.2M | −$52.9M | −36.21% |
| Q1 2025 | 2025-03-31 | $110.3M | −$46.8M | −29.79% |
| Q4 2024 | 2024-12-31 | $125.2M | −$23.3M | −15.69% |
| Q3 2024 | 2024-09-30 | $138.4M | −$21.6M | −13.53% |
| Q2 2024 | 2024-06-30 | $146.1M | −$22.2M | −13.18% |
| Q1 2024 | 2024-03-31 | $157.1M | −$18.2M | −10.39% |
| Q4 2023 | 2023-12-31 | $148.5M | −$33.1M | −18.22% |
| Q3 2023 | 2023-09-30 | $160.0M | $43.9M | +37.83% |
| Q2 2023 | 2023-06-30 | $168.3M | $41.4M | +32.58% |
| Q1 2023 | 2023-03-31 | $175.3M | $40.8M | +30.32% |
| Q4 2022 | 2022-12-31 | $181.6M | $41.6M | +29.67% |
| Q3 2022 | 2022-09-30 | $116.1M | $92.2M | +386.09% |
| Q2 2022 | 2022-06-30 | $126.9M | $98.1M | +339.58% |
| Q1 2022 | 2022-03-31 | $134.5M | $101.0M | +301.81% |
| Q4 2021 | 2021-12-31 | $140.1M | $100.1M | +250.68% |
| Q3 2021 | 2021-09-30 | $23.9M | −$23.4M | −49.48% |
| Q2 2021 · Jun 30 | 2021-06-30 | $28.9M | −$24.4M | −45.77% |
| Q1 2021 · Mar 31 | 2021-03-31 | $33.5M | $158.2M | — |
| Q4 2020 · Dec 31 | 2020-12-31 | $39.9M | $28.7M | +254.53% |
| Q2 2021 · Sep 30 | 2020-09-30 | $47.3M | $159.5M | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $53.3M | $157.2M | — |
| Q4 2020 · Mar 31 | 2020-03-31 | −$124.8M | −$124.7M | — |
| Q4 2019 · Dec 31 | 2019-12-31 | $11.3M | $11.3M | — |
| Q2 2020 | 2019-09-30 | −$112.2M | −$112.2M | — |
| Q1 2020 | 2019-06-30 | −$103.9M | −$103.9M | — |
| Q4 2019 · Mar 31 | 2019-03-31 | −$70,589 | −$36,037 | — |
| Q3 2019 | 2018-12-31 | −$61,724 | — | — |
| Q2 2019 | 2018-09-30 | −$51,582 | — | — |
| Q1 2019 | 2018-06-30 | −$43,026 | — | — |
| As of Mar 31, 2018 | 2018-03-31 | −$34,552 | — | — |
Compass Therapeutics shareholders’ equity trends
Over the last five fiscal years, Compass Therapeutics's shareholders’ equity increased from $39.9M to $196.8M, a change of $156.8M. The latest reported quarter, Q2 2026, shows $166.0M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗